Seegene Reports Q1 Revenue of KRW 129.1 Billion and Operating Profit of KRW 23.6 Billion, Driven by Growth in Non-Respiratory Product Portfolio

On May 8, Seegene, a global total solution provider in molecular diagnostics, announced through a public disclosure that it continued to improve profitability in the first quarter of this year, backed by steady sales growth in its non-respiratory product portfolio and stable revenue expansion.

According to its consolidated provisional results, Seegene's revenue for the first quarter of this year reached KRW 129.1 billion, marking an 11.3% year-on-year increase. Operating profit was KRW 23.6 billion, up 58.6% from the same period last year, continuing the profitability improvements seen in the previous quarter.

The main driver of Seegene's robust sales growth this quarter was its non-respiratory syndromic product line, which posted a 32.6% increase in sales compared to the same period last year. Individually, the gastrointestinal (GI), human papillomavirus (HPV), and sexually transmitted infection (STI) product lines each achieved growth of over 30%. Syndromic diagnostics refer to next-generation molecular diagnostic methods that can simultaneously test for multiple pathogens using a single specimen, enhancing diagnostic efficiency and clinical utility.

The company attributed the rise in sales primarily to its successful bids for the HPV product line and expanded entry into the screening market. In particular, it stated that the continued growth of the GI and STI product lines is supported by increasing demand for a transition to PCR-based diagnostics and strong product competitiveness. Additionally, although the respiratory product line was affected by fluctuations in disease incidence, overall sales growth momentum was maintained.

As for the increase in operating profit, the company explained that profitability improved due to sales growth based on product competitiveness, alongside enhancements in cost structure and operational efficiency. The cost ratio for products and goods declined, and both selling and administrative expenses, as well as R&D expenditures, were efficiently managed, resulting in ongoing improvements in overall profitability.

By region, Europe maintained its position as the primary market, accounting for approximately 65% of total sales. Stable sales were also recorded in other regions such as Asia (13.9%), the Americas (13.3%), and Korea (7.4%). The company stated that it will continue to pursue global market expansion based on its stable, Europe-centered sales foundation.

Seegene is also focusing on advancing its data-driven diagnostics and automation strategies. The company presented its real-time test data analytics statistical platform STAgora™—which connects global PCR test data to provide statistics-based insights—and its unmanned PCR automation system CURECA™—which automates the entire PCR workflow—at global conferences such as ESCMID Global 2026, outlining its future diagnostic business strategy based on data and automation.

Kim Jungyong, Chief Financial Officer of Seegene, said, "The growth led by our non-respiratory product portfolio is steadily expanding our revenue base," adding, "While continuing to improve profitability through cost structure optimization and efficiency, we will strengthen our foundation for mid- to long-term growth by integrating data and automation into our diagnostic strategy."

This content was produced with the assistance of AI translation services.